Influence of Beta Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04485988

Enrollment

3000

Registered

2020-07-24

Start date

2015-07-01

Completion date

2021-07-31

Last updated

2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMI

Brief summary

To understand the effect of beta blockers on the prognosis of patients with acute myocardial infarction with preserved ejection fraction.

Detailed description

The use of beta blockers is an important component of drug therapy for myocardial infarction, but in some exceptional cases, evidence-based evidence for their use is insufficient, and we seek to understand the prognostic impact of beta blockers on patients enrolled in long-term follow-up.

Interventions

DRUGBeta blocker

Duration of medication

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Patients with acute myocardial infarction

Exclusion criteria

* Previous history of heart failure admission Killip class \> I class cancer pregnant

Design outcomes

Primary

Measure	Time frame	Description
Death	The median time of 3 years	all-cause mortality

Countries

China

Contacts

Primary Contactdongying zhang, doctor

zhangdongying@cqmu.edu.cn86.27.8901.1596

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026